Individualized homeopathic medicines in the treatment of premenstrual syndrome: A double-blind, randomized, placebo-controlled trial

被引:0
|
作者
Sahoo, Sanjib [1 ]
Nayak, Chintamani [1 ]
Rath, Prasanta [2 ]
Bhattacharya, Soumya [3 ]
Mukherjee, Suranjana [3 ]
Dutta, Abhijit [4 ]
机构
[1] Natl Inst Homoeopathy, Dept Homoeopath Mat Med, Kolkata, India
[2] Natl Inst Homoeopathy, Dept Community Med, Kolkata, India
[3] Natl Inst Homoeopathy, Dept Homoeopath Pharm, Kolkata, India
[4] Minist Ayush Govt India, Int Cooperat Sect, New Delhi, India
关键词
Premenstrual syndrome; Homeopathy; Randomized controlled trial; Placebo; SPAF; PMTS; DYSPHORIC DISORDER;
D O I
10.1016/j.explore.2024.103039
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Introduction: Background: Premenstrual syndrome (PMS) is a common disorder among female population that adversely affects their physical and emotional well-being. Conventional treatments for PMS may have limitations and side effects, prompting a need for complementary therapeutic approaches. This double-blind, randomized, placebo-controlled trial aimed to investigate the efficacy of individualized Homeopathic medicines (IH) in treating PMS symptoms in comparison to placebo (PL). Methods: This study recruited female participants of reproductive age who had been experiencing premenstrual syndrome (PMS) for >3 months, from the Outpatient Department. The participants were randomly assigned to receive either IH or PL. The measured outcomes included the Shortened Premenstrual Assessment Form (SPAF) questionnaire as the primary outcome, and the Premenstrual Tension Syndrome Visual Analogue Scale (PMTS-VAS) and the Premenstrual Tension Syndrome Observer Rating Scale - Revised (PMTS-OR) as secondary outcomes. These measures were assessed at baseline and every month for 3 months. Results: The results showed a statistically significant reduction in total SPAF scores for the IH group compared to the placebo group (F = 11.340; P < 0.001) at month 2 (-5.5 +/- 1.8, P = 0.003), and month 3 (-6.6 +/- 2.0, P = 0.002). Additionally, there were significant reductions in PMTS-VAS and PMTS-OR scores in the IH compared to placebo group. Natrum muriaticum (n = 4/30, 13.3 %) was the most frequently indicated medicines in the study. Four adverse events (13.33 %) occurred in the IH group, and six adverse events (16.67 %) in the Placebo group, with no serious events reported, and no additional medicinal treatment was required for participants during the study period. Conclusions: Individualized Homeopathic medicines were found to be significantly effective, compared to placebo in reducing PMS symptoms. Further independent replication is warranted to validate and corroborate these findings, as well as to identify the most effective Homeopathic medicines for treating PMS symptoms. Until then, clinicians may consider these findings when exploring personalized and holistic therapeutic strategies for managing PMS.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Metoclopramide for the treatment of Tourette syndrome: A randomized, double-blind, placebo-controlled trial
    Nicolson, R
    Smith, J
    Castellanos, FX
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S277 - S277
  • [32] Milnacipran for the treatment of fibromyalgia syndrome: A randomized, double-blind, placebo-controlled trial
    Clauw, Daniel J.
    Palmer, Robert H.
    Thacker, Kim
    Gendreau, R. Michael
    Mease, Philip
    NEUROLOGY, 2008, 70 (11) : A162 - A162
  • [33] A DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF PROGESTERONE VAGINAL SUPPOSITORIES IN THE TREATMENT OF PREMENSTRUAL-SYNDROME
    MADDOCKS, S
    HAHN, P
    MOLLER, F
    REID, RL
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1986, 154 (03) : 573 - 581
  • [34] Individualized Homeopathic Medicinal Products in the Treatment of Post-COVID-19 Conditions: A Double-Blind, Randomized, Placebo-Controlled, Feasibility Trial
    Rana, Abhijit
    Bhattacharya, Pulakendu
    Ganguly, Subhasish
    Saha, Sangita
    Naskar, Satyajit
    Ghosh, Shubhamoy
    Shaikh, Abdur Rahaman
    Koley, Munmun
    Saha, Subhranil
    Mukherjee, Shyamal Kumar
    JOURNAL OF INTEGRATIVE AND COMPLEMENTARY MEDICINE, 2025, 31 (01): : 64 - 74
  • [35] Individualized homeopathic medicines in preventing the progression from pre-diabetes to diabetes: A double-blind, randomized, placebo-controlled, parallel-arm trial
    Banerjee, Aryabrata
    Ganguly, Subhasish
    Saha, Sangita
    Bhattacharyya, Pulakendu
    Naskar, Satyajit
    Mukherjee, Debraj
    Ghosh, Shuvadip
    Maji, Prosenjit
    Saha, Subhranil
    Shaikh, Abdur Rahaman
    Ghosh, Priyanka
    Chatterjee, Chandrima
    Koley, Munmun
    Mukherjee, Shyamal Kumar
    EXPLORE-THE JOURNAL OF SCIENCE AND HEALING, 2024, 20 (05)
  • [36] Homeopathic treatment of mild traumatic brain injury: A randomized, double-blind, placebo-controlled clinical trial
    Chapman, EH
    Weintraub, RJ
    Milburn, MA
    Pirozzi, TO
    Woo, E
    JOURNAL OF HEAD TRAUMA REHABILITATION, 1999, 14 (06) : 521 - 542
  • [37] TREATMENT OF PREMENSTRUAL-SYNDROME WITH ALPRAZOLAM - RESULTS OF A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED CROSSOVER CLINICAL-TRIAL
    SMITH, S
    RINEHART, JS
    RUDDOCK, VE
    SCHIFF, I
    OBSTETRICS AND GYNECOLOGY, 1987, 70 (01): : 37 - 43
  • [38] Homeopathic Treatment of Chronic Low-Back Pain: A Double-Blind, Randomized, Placebo-Controlled Trial
    Muduli, Sagarika
    Sarkar, Sanjib
    Pal, Rajat Kumar
    Ghosh, Shubhamoy
    Alam, Sk. Monsur
    Saha, Subhranil
    Naskar, Satyajit
    Roy, Suhasish
    Saha, Ankit
    Halder, Indrani
    Ghosh, Priyanka
    Shaikh, Abdur Rahaman
    Koley, Munmun
    Mukherjee, Shyamal Kumar
    JOURNAL OF INTEGRATIVE AND COMPLEMENTARY MEDICINE, 2025,
  • [39] PREMENSTRUAL SYNDROME - DOUBLE-BLIND CONTROLLED TRIAL OF PROGESTERONE AND PLACEBO
    SAMPSON, GA
    BRITISH JOURNAL OF PSYCHIATRY, 1979, 135 (SEP) : 209 - 215
  • [40] Effect of Peppermint Oil on Premenstrual Syndrome: A Randomized, Double-Blind Placebo-Controlled Study
    Delavar, Mouloud Agajani
    Ebrahimi, Soheila
    Esmaeilzadeh, Sedigheh
    Khamse, Azam
    IRANIAN RED CRESCENT MEDICAL JOURNAL, 2019, 21 (03)